Boehringer Ingelheim

An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities

Official Title: 
Expanded Access Use of OFEV (Nintedanib) in Non-IPF Interstitial Lung Disease
Brief Summary: 
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
EA Type
Individual Patients
Lung Diseases, Interstitial

Drug: OFEV
twice daily

Eligibility Criteria: 

Inclusion Criteria:


Exclusion Criteria:

- Patients who are eligible for and can participate in an ongoing non Idiopathic Pulmonary
Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded from participation
in this Expanded Access Program (EAP).

Eligibility Gender: 
United States

Banner University Medical Center Tucson
Tucson, Arizona, 85724


Investigator: Sachin Chaudhary
Contact: +001 (520) 626-8000

University of Rochester Medical Center
Rochester, New York, 14559


Investigator: Robert Kottmann
Contact: +001 (585) 275-4861

Centra Medical Group
Bedford, Virginia, 24523


Investigator: Stephen Johnson
Contact: +001 (434) 390-4182

Inova Fairfax Medical Campus
Falls Church, Virginia, 22042


Investigator: Oksana Shlobin
Contact: +001 (703) 776-2256


Boehringer Ingelheim

Boehringer Ingelheim
EA Number: 
MeSH Terms: 
Lung Diseases, Lung Diseases, Interstitial, Nintedanib
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about